Results 31 to 40 of about 22,654,637 (305)

Lista de Avaliadores 2020

open access: yesRevista Ciências em Saúde, 2020
Os Editores da Revista Ciências em Saúde, do Hospital de Clínicas de Itajubá, agradecem o primoroso e voluntário trabalho oferecido pelos profissionais listados abaixo, que serviram como pareceristas ad hoc durante o ano de 2020.
Health Sciences Journal
doaj   +1 more source

Dexamethasone for Chemotherapy‐Induced Nausea and Vomiting Prevention in Pediatric Patients: International Consensus

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background An international Delphi panel of experts developed consensus statements to delineate the circumstances where the risks of dexamethasone as an antiemetic do and do not outweigh its benefits. Procedure Experts in supportive care of pediatric patients were invited to participate.
Negar Shavandi   +20 more
wiley   +1 more source

Providing health checks as incentives to retain blood donors — evidence from two field experiments [PDF]

open access: yes, 2018
The collection of blood given by donors has proven to be a substantial societal and a managerial challenge. Consequently, blood donation services seek for incentive mechanisms to retain donors.
Clement, Michel   +3 more
core   +1 more source

Real‐World Pediatric Blinatumomab Administration: Access to Outpatient Care Delivery and Impact of a Hospital‐Dispensed Model

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Blinatumomab has been shown to be highly effective for patients with pediatric B‐ALL and has recently become standard of care therapy. Due to its past use in the clinical trial setting, there is limited information available about real‐world administration.
Katelyn Oranges   +12 more
wiley   +1 more source

Clinical Insights Into Hypercalcemia of Malignancy in Childhood

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Hypercalcemia of malignancy (HCM) is a rare but life‐threatening metabolic emergency in children that occurs in less than 1% of pediatric cancer cases, with a reported incidence ranging from 0.4% to 1.0% across different studies. While it is observed in 10%–20% of adult malignancies, pediatric HCM remains relatively uncommon.
Hüseyin Anıl Korkmaz
wiley   +1 more source

Survival Outcomes and Complications Among Canadian Children With Retinoblastoma: A Population‐Based Report From CYP‐C

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Retinoblastoma (RB) is the most common pediatric ocular cancer, yet population‐based data on survival and risk factors remain limited. This study aimed to describe survival in a large national RB cohort and identify predictors of death and complications.
Samuel Sassine   +14 more
wiley   +1 more source

A Comprehensive Analysis on the Healthcare Systems in Latin America [PDF]

open access: yes, 2019
This comprehensive report summarizes and analyzes the current state of healthcare in Latin America, specifically in the countries of Mexico, Brazil, the Northern Triangle (El Salvador, Guatemala, and Honduras), the Andean Region (Ecuador, Peru, and ...
Calderon, Melinda   +5 more
core   +1 more source

Think Health � Speak Health � Achieve Health [PDF]

open access: yesOA Family Medicine, 2013
Introduction: Health has been lost in the current healthcare system, replaced by a near exclusive focus on discrete diseases. People feel healthy if they perceive a relative balance between their physical, emotional, social and cognitive experiences. The role of the healthcare system, therefore, must be to facilitate a rebalancing of these domains in ...
openaire   +1 more source

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács   +8 more
wiley   +1 more source

Anti-TNF in Rheumatic Diseases: Inventory and Outlook

open access: yesEuropean Medical Journal Rheumatology, 2018
With an increasing number of biosimilars receiving regulatory approval, the treatment landscape for rheumatic diseases is evolving. Healthcare professionals (HCP) are being presented with an expanding armamentarium of treatment options that can increase ...
Syneos Health
doaj  

Home - About - Disclaimer - Privacy